通过阻断这种蛋白质,注射Keytruda疗法可以使患者自身的免疫细胞攻击体内的肿瘤细胞。 参考来源:NICE approves Merck’s Keytruda for adult patients with rare triple negative breast cancer
帕姆单抗(Keytruda对 breast cancer的治疗效果及其对病人基因检测的要求 帕姆单抗(Keytruda)是一种免疫疗法药物,被广泛用于乳腺癌的治疗。它通过抑制肿瘤细胞上的PD-1受体,激活免疫系统,增强对癌细胞的攻击能力。研究表明,帕姆单抗可以显著延长乳腺癌患者的生存期,并提高治疗效果。 然而,帕姆单抗对乳腺癌的治疗效果与患者...
(生物谷Bioon.com) 原文出处:FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery 版权声明 本网站所有注明“...
此前,FDA已授予Keytruda+化疗用于高危早期TNBC患者新辅助治疗的突破性药物资格(BTD)。 原文出处:Merck Announces Two US Regulatory Milestones for KEYTRUDA (pembrolizumab) in Triple-Negative Breast Cancer (TNBC) 注:以上资讯来源于网络,由香港济民药业整理编辑(如有错漏,请帮忙指正),只为提供全球最新上市药品的资...
[2] New drug combination for aggressive breast cancer could save thousands of lives. Retrieved February 11, 2022 from https://medicalxpress.com/news/2022-02-drug-combination-aggressive-breast-cancer.html (原文有删减)
Keytruda联合化疗患者的死亡率降低了34%。此次Keytruda联合化疗获得批准治疗乳腺癌，将允许与Keytruda在所有27个欧盟成员国以及冰岛、列支敦士登、挪威和北爱尔兰进行上市营销。这也是Keytruda在欧盟首次获批用于治疗乳腺癌。参考来源：EU Approves Merck's Keytruda Plus Chemotherapy To Treat Triple-Negative Breast Cancer ...
(pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) Published in the New England Journal of Medicine. Retrieved February 10, 2022, from https://www.merck.com/news/pivotal-phase-3-data-for-keytruda-pembrolizumab-in-high-risk-early-stage-triple-negative-breast-cancer-...
原文出处:European Commission Approves KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced or Early-Stage Triple-Negative Breast Cancer at High Risk of Recurrence ...
与其他乳腺癌类型相比,三阴性乳腺癌侵袭性强,更易出现远处转移及复发,且传统的激素疗法治疗效果较差,临床治疗选择有限,因此急需更有效的治疗手段。近年来,免疫治疗的出现为三阴性乳腺癌的治疗带来了新的治疗方向,也让更多三阴性乳腺癌患者受益。 三...
[3] Adding Ribociclib to First-Line Endocrine Therapy Significantly Improves Survival for Pre-Menopausal Women With Advanced Breast Cancer, Retrieved June 1, 2019, from https://www.asco.org/about-asco/press-center/news-releases/adding-ribociclib-first-line-endocrine-therapy-significantly ...